Dianthus Therapeutics, Inc. (DNTH)
(Real Time Quote from BATS)
$21.85 USD
-0.31 (-1.40%)
Updated May 30, 2024 10:20 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Price, Consensus and EPS Surprise
DNTH 21.85 -0.31(-1.40%)
Will DNTH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DNTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DNTH
The Zacks Analyst Blog Highlights American Eagle Outfitters, Abercrombie & Fitch, Cimpress, Dianthus Therapeutics and NVIDIA Corporation
Strong Q1 a Boon for the Rest of 2024? 5 Top Growth Picks
DNTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
Other News for DNTH
Dianthus Therapeutics Enhances Incentives and Affirms Governance
Intel upgraded, Texas Instruments initiated: Wall Street's top analyst calls
Analysts’ Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), GoodRx Holdings (GDRX) and Dianthus Therapeutics (DNTH)
Dianthus Therapeutics’ DNTH103: A Potential Game-Changer in Autoimmune Disease Treatment
Dianthus initiated with bullish view at H.C. Wainwright, here's why